SCHEMBL14980405

SCHEMBL14980405

CN1CCC(NCCOCCOCCOCCO)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 1/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MITF O75030 1/20 0.36
THRB P10828 1/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 2/20 0.34
FOXM1 Q08050 1/20 0.33
MAPK1 P28482 1/20 0.33
CHRM1 P11229 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM3 P20309 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19464799 0.84 KDM4E (0.37) MEN1KMT2ATHRBHTTMAPT
SCHEMBL21940877 0.83 HRH3 (0.37) MEN1KMT2ATHRBHTTMAPT
SCHEMBL16219517 0.83 MEN1 (0.33) MEN1KMT2ATHRBHTTMAPT
SCHEMBL22479349 0.81 MEN1 (0.38) DPP7MEN1KMT2AMITFHTT
SCHEMBL4623324 0.80 DPP7 (0.45) DPP7MEN1KMT2AMITFADRB2
SCHEMBL16754244 0.78 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2TSHRFOXM1
Hydrochloric Acid SCHEMBL4885466 0.78 DPP7 (0.44) DPP7MEN1KMT2AMITFADRB2
SCHEMBL16754235 0.78 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2TSHRFOXM1
SCHEMBL24204664 0.78 MEN1 (0.47) DPP7MEN1KMT2AMITFADRB2
SCHEMBL16754258 0.77 SMN1; SMN2 (0.45) MEN1KMT2ASMN1; SMN2TSHRFOXM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 DPP7 2669/4885MEN1 4108/4885KMT2A 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.